UnitedHealth Group Incorporated (UNH) Outlook Strong, Analysts Watch Closely

UnitedHealth Group Incorporated (NYSE:UNH) is among the stocks Wall Street analysts are watching closely. On November 11, Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400. Earlier on November 3, a Barclays analyst had also maintained his Buy rating and a $386 price target. Analysts’ opinion on the stock is currently tilting towards the positive, with the consensus 1-year median price target of $410 implying a 28% potential upside.

On the business side, on November 18, UnitedHealth Group Incorporated (NYSE:UNH) announced the addition of ex-commissioner of the U.S. Food and Drug Administration, Scott Gottlieb, to its board, effective immediately.

Having previously served as the FDA chief from 2017 to 2019 and later at U.S. drugmaker Pfizer, Gottlieb is widely recognized by public health advocates for his efforts in reducing flavored e-cigarette use among youths. He has also played a pivotal role in intensifying competition through speedy approvals.

“I hope to leverage my experience to support providers in their delivery of care that’s not only more innovative but also more affordable, and that improves outcomes for patients and communities,” he said.

UnitedHealth Group Incorporated (NYSE:UNH) is a Minnesota-based healthcare company operating through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. Founded in 1974, the company is committed to improving the healthcare system.

While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.